BIOMAT Database Logo BIOMAT Database Logo

Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (enoxaparin) 1997

J L Pèrez-Requejo, and O Lucena-Solano, and M Pérez-García, and M T Santarelli
Centro Policlinico Valencia, Venezuela.

Some previous reports indicated that a minimal amount of anti-IIa is necessary for the optimal anti-Xa activity of low molecular weight heparin (LMW-H). To know if we could improve the prophylactic activity of LMW-H, providing a mild antithrombin effect, we conducted an experiment in which we administered subcutaneously to 10 volunteers, very low doses of unfractionated heparin (UFH), (1000 IU), a LMW-H (enoxaparin, 2000 IU = 20mg), or both heparins together on alternate days, and measure the anti-Xa activity before, and 4 hours after injection. We found that the anti-Xa activity in the first group (UFH), increased by 33%, over the basal values; in the second group (LMW-H), by 93%, but it increased by 282%, in the third group (UFH + LMW-H) showing clearly (p < 0.0069), that UFH could increase synergistically, more than additive, the anti-Xa activity of enoxaparin. The impact on the cost-effectiveness of antithrombotic prophylaxis and the therapeutic results with the herein combined scheme should be evaluated.

UI MeSH Term Description Entries
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D065427 Factor Xa Inhibitors Endogenous factors and drugs that inhibit or block the activity of FACTOR XA. Direct Factor Xa Inhibitor,Direct-Acting Oral Anticoagulant,Direct-Acting Oral Anticoagulants,Factor Xa Inhibitor,Direct Factor Xa Inhibitors,Anticoagulant, Direct-Acting Oral,Anticoagulants, Direct-Acting Oral,Direct Acting Oral Anticoagulant,Direct Acting Oral Anticoagulants,Inhibitor, Factor Xa,Oral Anticoagulant, Direct-Acting,Oral Anticoagulants, Direct-Acting,Xa Inhibitor, Factor

Related Publications

J L Pèrez-Requejo, and O Lucena-Solano, and M Pérez-García, and M T Santarelli
Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin.
June 1999, British journal of obstetrics and gynaecology,
J L Pèrez-Requejo, and O Lucena-Solano, and M Pérez-García, and M T Santarelli
Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin.
July 1998, British journal of obstetrics and gynaecology,
J L Pèrez-Requejo, and O Lucena-Solano, and M Pérez-García, and M T Santarelli
Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane).
August 1994, Thrombosis and haemostasis,
J L Pèrez-Requejo, and O Lucena-Solano, and M Pérez-García, and M T Santarelli
Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin.
July 1985, Seminars in thrombosis and hemostasis,
J L Pèrez-Requejo, and O Lucena-Solano, and M Pérez-García, and M T Santarelli
Anti-Xa activity with low-molecular-weight heparin, enoxaparin, during pregnancy in women with mechanical heart valves.
January 2002, Proceedings of the Western Pharmacology Society,
J L Pèrez-Requejo, and O Lucena-Solano, and M Pérez-García, and M T Santarelli
Heparin and low molecular weight heparin: is anti-factor Xa activity important?
October 1989, The Journal of laboratory and clinical medicine,
J L Pèrez-Requejo, and O Lucena-Solano, and M Pérez-García, and M T Santarelli
Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
September 2014, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,
J L Pèrez-Requejo, and O Lucena-Solano, and M Pérez-García, and M T Santarelli
Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation.
November 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
J L Pèrez-Requejo, and O Lucena-Solano, and M Pérez-García, and M T Santarelli
Haemorrhagic effect of enoxaparin, a low molecular weight heparin. Comparison with unfractionated heparin in humans.
November 1992, Scandinavian journal of gastroenterology,
J L Pèrez-Requejo, and O Lucena-Solano, and M Pérez-García, and M T Santarelli
Stability of plasma anti-Xa activity in low-molecular-weight heparin monitoring.
June 2010, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
Copied contents to your clipboard!